20 results
1. To study the effect of different target PaO2's on myocardial damage, hemodynamics, microcirculation and organ perfusion in CABG patients.2. To study underlying mechanisms of hyperoxia by determining differences in oxidative stress response…
Primary Study Objectives:This study tries to objectives the potential benefit of prophylactic HBOT in terms of reducing / limiting the amount of dysphagia and / or xerostomia for tumors in the head and neck, specifically originating from the…
This is a phase I/II pediatric dose-ranging study that will evaluate the safety, tolerability and pharmacokinetics of midostaurin in children <18 years of age and >= 3 months who have relapsed or refractory leukemias that may benefit…
Primary: To study the efficacy and tolerability of Midostaurin in patients with indolent or smoldering systemic mastocytosis on mediator symptom reduction.Secondary: 1) To study whether Midostaurin can reduce mast cell infiltration and 2) to assess…
To explore the dose-response relationship between supplemental oxygen and sublingual microcirculatory perfusion and hemodynamics in healthy volunteers
Objective of this study is to determine the efficacy of midostaurin in patients with ASM or MCL with/without an associated hematological clonal non-mast cell lineage disease.
This research project aims to investigate whether hyperoxic interval training improves whole body insulin resistance, endothelial dysfunction, cardiovascular fitness, lipid metabolism and glycemic control in the treatment of deconditioned non-…
To determine if the addition of midostaurin to daunorubicin/ cytarabine induction, high dose cytarabine consolidation, and continuation therapy improves overall survival (OS) in both the mutant FLT3-ITD and FLT-3 TKD AML patients.
1. To study the short- and long-term effect of different target PaO2's on circulatory status, organ dysfunction and outcome.2. To study underlying mechanisms of hyperoxia by determining differences in oxidative stress response between the…
Primary: To determine the MTD and/or RDE of LGH447 with or without midostaurin. Secondary: 1. To characterize the safety and tolerability of LGH447 with or without midostaurin at the MTD and/or RDE.2. To assess any observed antitumor activity of…
To investigate the effect of maternal hyperoxygenation with 100% in the second stage of labor and in the presence of abnormal fetal heart rate (FHR) patterns on fetal condition, instrumental delivery rate and free radical production. In case a…
To assess the benefits and harms of two targets of partial pressure of oxygen in arterial blood (PaO2) in guiding the oxygen administration in acutely ill adults with hypoxaemic respiratory failure at ICU admission.
Primary objective:To asses the safety and feasibility of post-transplant panobinostat combined with midostaurin in patients with adverse risk AML/RAEB with FLT3-ITD with high allelic ratio in terms of dose limiting toxicity.Secondary objectives:To…
To study the relation between PaO2/FiO2-ratio and FiO2
The main aim is to compare the effect of a restrictive versus liberal oxygen strategy the first eight hours after trauma on the incidence of 30-day mortality and/or major respiratory complications (pneumonia and ARDS) within 30 days (combined…
Primary objectives:- To assess in a randomized comparison the effect of midostaurin added to 10-day decitabine treatment on the cumulative CR/CRi rate during 3 cycles.Secondary objectives:- To assess the safety and tolerability of midostaurin added…
To assess whether HBOT reduces pain, and improves physical functioning and QoL in breast cancer patients with late radiation toxicity.
The objective of this study is to investigate whether hyperbaric oxygen therapy twice-daily for five days (HBOT5) is superior to hyperbaric oxygen therapy once daily for ten days (HBOT10) in obtaining hearing loss recovery after AAT. This will be…
To assess clinical improvement of skin severity in patients with ichthyosis
To compare OS between gilteritinib and midostaurin in combination with induction therapy and consolidation therapy followed by one-year maintenance therapy in patients with newly diagnosed AML with a FLT3 gene mutation eligible for intensive…